Welcome to our dedicated page for SELLAS Life Sciences Group SEC filings (Ticker: SLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SELLAS Life Sciences Group, Inc. filings document a Nasdaq-listed clinical biopharmaceutical company developing cancer therapeutics, including GPS and SLS009 programs in acute myeloid leukemia. Form 8-K reports cover operating results, financial condition, corporate updates, clinical program disclosures, and material agreements.
The filing record also includes capital-structure disclosures for common stock and warrants, warrant inducement agreements and exercise proceeds, share-count updates, and facility-related agreements. Proxy materials document annual meeting proposals, stockholder voting procedures, and governance matters.
The Form 8-K filed by SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) discloses the voting results from the Company’s Annual Meeting held on June 17, 2025. Of the 94.5 million shares outstanding, 61.3 million (64.85%) were present or represented by proxy.
- Board elections: Class III directors Angelos M. Stergiou and John Varian were re-elected, receiving 83% and 84% of votes cast, respectively, excluding broker non-votes.
- Auditor ratification: Stockholders confirmed Baker Tilly US, LLP as independent auditor for FY 2025 with a strong 86.9% “For” vote.
- Equity plan amendment: An increase of 800,000 shares under the 2021 Employee Stock Purchase Plan was approved (66% “For”).
- Say-on-pay: The advisory resolution on executive compensation passed with 69% support.
- Say-on-frequency: A plurality of holders (74%) preferred an annual vote on executive compensation.
- Adjournment authority: Shareholders granted the Board discretion to adjourn the meeting if additional proxy solicitation were needed.
No other matters were presented, and no financial performance data or strategic transactions were reported in this filing.